New therapeutic options for advanced forms of thyroid cancer

Bibliography

• SEER Stat fact sheets: thyroid Cancer. Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute. 2013. Available from: http://seer.cancer.gov/statfacts/html/thyro.html [Last accessed 21 November 2013]
   Google Scholar
• Davies L, Welch HG. Increasing incidence of thyroid cancer in the united states, 1973-2002. JAMA 2006;295:2164-7
   PubMed Web of Science ®Google Scholar
• Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National cancer data base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer 1998;83:2638-48
   PubMed Web of Science ®Google Scholar
• Pelizzo MR, Boschin IM, Bernante P, et al. Natural history, diagnosis, treatment and outcome of medullary thyroid cancer: 37 years experience on 157 patients. Eur J Surg Oncol 2007;33:493-7
   PubMed Web of Science ®Google Scholar
• Saad MF, Ordonez NG, Rashid RK, et al. Medullary carcinoma of the thyroid. A study of the clinical features and prognostic factors in 161 patients. Medicine (Baltimore) 1984;63:319-42
   PubMed Web of Science ®Google Scholar
• Lips CJ, Landsvater RM, Höppener JW, et al. Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A. N Engl J Med 1994;331(13):828-35
   PubMed Web of Science ®Google Scholar
• Bergholm U, Bergström R, Ekbom A. Long-term follow-up of patients with medullary carcinoma of the thyroid. Cancer 1997;79(1):132-8
   PubMed Web of Science ®Google Scholar
• Sherman SI, Brierley JD, Sperling M, et al. Prospective multicenter study of thyroid-carcinoma treatment: initial analysis of staging and outcome. National thyroid cancer treatment cooperative study registry group. Cancer 1998;83:1012-21
   PubMed Web of Science ®Google Scholar
• Greene FL, Page DL, Fleming ID, et al., editors. AJCC cancer staging manual. 6th edition. Springer-Verlag, New York; 2002. p. 435
   Google Scholar
• Elisei R, Schlumberger MJ, Müller SP, et al. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol 2013;31:3639-46
   PubMed Web of Science ®Google Scholar
• Boichard A, Croux L, Al Ghuzlan A, et al. Somatic RAS mutations occur in a large proportion of sporadic RET-negative medullary thyroid carcinomas and extend to a previously unidentified exon. J Clin Endocrinol Metab 2012;97:E2031-5
   PubMed Web of Science ®Google Scholar
• Smallridge RC. Approach to the patient with anaplastic thyroid carcinoma. J Clin Endocrinol Metab 2012;97(8):2566-72
   PubMed Web of Science ®Google Scholar
• Smallridge RC, Ain KB, Asa SL, et al. American thyroid association anaplastic thyroid cancer guidelines taskforce. American thyroid association guidelines for management of patients with anaplastic thyroid cancer. Thyroid 2012;22:1104-39
   PubMed Web of Science ®Google Scholar
• Kebebew E, Greenspan FS, Clark OH, et al. Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer 2005;103:1330-5
   PubMed Web of Science ®Google Scholar
• Sherman SI. Cytotoxic chemotherapy for differentiated thyroid carcinoma. Clin Oncol (R Coll Radiol) 2010;22(6):464-8
   PubMed Web of Science ®Google Scholar
• McGriff NJ, Csako G, Gourgiotis L, et al. Effects of thyroid hormone suppression therapy on adverse clinical outcomes in thyroid cancer. Ann Med 2002;34:554-64
   PubMed Web of Science ®Google Scholar
• Jonklaas J, Sarlis NJ, Litofsky D, et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid 2006;16:1229-42
   PubMed Web of Science ®Google Scholar
• Terezakis SA, Lee KS, Ghossein RA, et al. Role of external beam radiotherapy in patients with advanced or recurrent nonanaplastic thyroid cancer: memorial sloankettering cancer center experience. Int J Radiat Oncol Biol Phys 2009;73:795-801
   PubMed Web of Science ®Google Scholar
• Schwartz DL, Lobo MJ, Ang KK, et al. Postoperative external beam radiotherapy for differentiated thyroid cancer: outcomes and morbidity with conformal treatment. Int J Radiat Oncol Biol Phys 2009;74:1083-91
   PubMed Web of Science ®Google Scholar
• Monchik JM, Donatini G, Iannuccilli J, Dupuy DE. Radiofrequency ablation and percutaneous ethanol injection treatment for recurrent local and distant well-differentiated thyroid carcinoma. Ann Surg 2006;244:296-304
   PubMed Web of Science ®Google Scholar
• Lewis BD, Hay ID, Charboneau JW, et al. Percutaneous ethanol injection for treatment of cervical lymph node metastases in patients with papillary thyroid carcinoma. AJR Am J Roentgenol 2002;178:699-704
   PubMed Web of Science ®Google Scholar
• Brose MS, Nutting C, Jarzab B, et al. Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: the phase III DECISION trial [abstract 4]. 2013 ASCO Annual Meeting; 2 June 2013; Chicago
   Google Scholar
• Schwartz DL, Rana V, Shaw S, et al. Postoperative radiotherapy for advanced medullary thyroid cancer--local disease control in the modern era. Head Neck 2008;30:883-8
   PubMed Web of Science ®Google Scholar
• Wells SA Jr, Robinson BG, Gagel RF, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 2012;30:134-41
   PubMed Web of Science ®Google Scholar
• Kim JH, Leeper RD. Treatment of locally advanced thyroid carcinoma with combination doxorubicin and radiation therapy. Cancer 1987;60:2372-5
   PubMed Web of Science ®Google Scholar
• Foote RL, Molina JR, Kasperbauer JL, et al. Enhanced survival in locoregionally confined anaplastic thyroid carcinoma: a single-institution experience using aggressive multimodal therapy. Thyroid 2011;21:25-30
   PubMed Web of Science ®Google Scholar
• Derbel O, Limem S, Ségura-Ferlay C, et al. Results of combined treatment of anaplastic thyroid carcinoma (ATC). BMC Cancer 2011;11:469
   PubMed Web of Science ®Google Scholar
• Aschebrook-Kilfoy B, Schechter RB, Shih YC, et al. The clinical and economic burden of a sustained increase in thyroid cancer incidence. Cancer Epidemiol Biomarkers Prev 2013;22:1252-9
   PubMed Web of Science ®Google Scholar
• Ramsey S, Blough D, Kirchhoff A, et al. Washington state cancer patients found to be at greater risk for bankruptcy than people without a cancer diagnosis. Health Aff (Millwood) 2013;32:1-10
   Google Scholar
• Response Evaluation Criteria In Solid Tumors (version 1.1). 2008. Available from: http://www.recist.com/ [Last accessed 24 November 2013]
   Google Scholar
• Anderson RT, Linnehan JE, Tongbram V, et al. Clinical, safety, and economic evidence in radioactive iodine-refractory differentiated thyroid cancer: a systematic literature review. Thyroid 2013;23:392-407
   PubMed Web of Science ®Google Scholar
• Lopez JP, Wang-Rodriguez J, Chang CY, et al. Gefitinib (iressa) potentiates the effect of ionizing radiation in thyroid cancer cell lines. Laryngoscope 2008;118:1372-6
   PubMed Web of Science ®Google Scholar
• Rothenberg SM, McFadden DG, Palmer E, et al. Re-differentiation of radioiodine-refractory BRAF V600E-mutant thyroid carcinoma with dabrafenib: a pilot study. J Clin Oncol 2013;31(Suppl):abstract 6025
   Google Scholar
• Ho AL, Grewal RK, Leboeuf R, et al. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N Engl J Med 2013;368:623-32
   PubMed Web of Science ®Google Scholar
• French JD. Revisiting immune-based therapies for aggressive follicular cell-derived thyroid cancers. Thyroid 2013;23:529-42
   PubMed Web of Science ®Google Scholar
• Reddi HV, Madde P, Cohen YC, et al. Antitumor activity of VB-111, a novel antiangiogenic virotherapeutic, in thyroid cancer xenograft mouse models. Genes Cancer 2011;2:993-5
   PubMedGoogle Scholar
• Kimura ET, Nikiforova MN, Zhu Z, et al. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 2003;63:1454-7
   PubMed Web of Science ®Google Scholar
• Marques AR, Espadinha C, Catarino AL, et al. Expression of PAX8-PPAR gamma 1 rearrangements in both follicular thyroid carcinomas and adenomas. J Clin Endocrinol Metab 2002;87:3947-52
   PubMed Web of Science ®Google Scholar
• American Thyroid Association Guidelines Task Force, Kloos RT, Eng C, Evans DB, et al. Medullary thyroid cancer: management guidelines of the american thyroid association. Thyroid 2009;19:565-612
   PubMed Web of Science ®Google Scholar
• Brauckhoff M, Gimm O, Weiss CL, et al. Multiple endocrine neoplasia 2B syndrome due to codon 918 mutation: clinical manifestation and course in early and late onset disease. World J Surg 2004;28:1305-11
   PubMed Web of Science ®Google Scholar
• Keefe SM, Cohen MA, Brose MS. Targeting vascular endothelial growth factor receptor in thyroid cancer: the intracellular and extracellular implications. Clin Cancer Res 2010;16:778-83
   PubMed Web of Science ®Google Scholar
• Kapiteijn E, Schneider TC, Morreau H, et al. New treatment modalities in advanced thyroid cancer. Ann Oncol 2012;23:10-18
   PubMed Web of Science ®Google Scholar
• Leboulleux S, Bastholt L, Krause T, et al. Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. Lancet Oncol 2012;13:897-905
   PubMed Web of Science ®Google Scholar
• Lam ET, Ringel MD, Kloos RT, et al. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol 2010;28:2323-30
   PubMed Web of Science ®Google Scholar
• Kloos RT, Ringel MD, Knopp MV, et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 2009;27:1675-84
   PubMed Web of Science ®Google Scholar
• Pennell NA, Daniels GH, Haddad RI, et al. A phase II study of gefitinib in patients with advanced thyroid cancer. Thyroid 2008;18:317-23
   PubMed Web of Science ®Google Scholar
• De Falco V, Buonocore P, Muthu M, et al. Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer. J Clin Endocrinol Metab 2013;98:E811-19
   PubMed Web of Science ®Google Scholar
• Schlumberger MJ, Elisei R, Bastholt L, et al. Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol 2009;27:3794-801
   PubMed Web of Science ®Google Scholar
• Carr LL, Mankoff DA, Goulart BH, et al. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res 2010;16:5260-8
   PubMed Web of Science ®Google Scholar
• Capdevila J, Iglesias L, Halperin I, et al. Sorafenib in metastatic thyroid cancer. Endocr Relat Cancer 2012;19:209-16
   PubMed Web of Science ®Google Scholar
• Cohen EE, Rosen LS, Vokes EE, et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol 2008;26:4708-13
   PubMed Web of Science ®Google Scholar
• Hoftijzer H, Heemstra KA, Morreau H, et al. Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. Eur J Endocrinol 2009;161:923-31
   PubMed Web of Science ®Google Scholar
• Ahmed M, Barbachano Y, Riddell A, et al. Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population. Eur J Endocrinol 2011;165:315-22
   PubMed Web of Science ®Google Scholar
• Bible KC, Suman VJ, Menefee ME, et al.; Mayo Phase 2 Consortium; Mayo Clinic Endocrine Malignances Disease Oriented Group. A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer. J Clin Endocrinol Metab 2012;97:3179-84
   PubMed Web of Science ®Google Scholar
• Bible KC, Suman VJ, Molina JR, et al.; Endocrine Malignancies Disease Oriented Group; Mayo Clinic Cancer Center; Mayo Phase 2 Consortium. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol 2010;11:962-72
   PubMed Web of Science ®Google Scholar
• Hayes DN, Lucas AS, Tanvetyanon T, et al. Phase II efficacy and pharmacogenomic study of selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements. Clin Cancer Res 2012;18:2056-65
   PubMed Web of Science ®Google Scholar
• Schneider TC, Abdulrahman RM, Corssmit EP, et al. Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trial. Eur J Endocrinol 2012;167:643-50
   PubMed Web of Science ®Google Scholar
• Gupta-Abramson V, Troxel AB, Nellore A, et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 2008;26:4714-19
   PubMed Web of Science ®Google Scholar
• de Groot JW, Zonnenberg BA, van Ufford-Mannesse PQ, et al. A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma. J Clin Endocrinol Metab 2007;92:3466-9
   PubMed Web of Science ®Google Scholar
• Brose MS, Nutting CM, Sherman SI, et al. Rationale and design of decision: a double-blind,randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer. BMC Cancer 2011;11:349
   PubMed Web of Science ®Google Scholar
• Sherman SI, Wirth LJ, Droz JP, et al.; Motesanib Thyroid Cancer Study Group. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med 2008;359:31-42
   PubMed Web of Science ®Google Scholar
• Lim SM, Chang H, Yoon MJ, et al. A multicenter, phase II trial of everolimus in locally advanced or metastatic thyroid cancer of all histologic subtypes. Ann Oncol 2013;24(12):3089-94
   PubMed Web of Science ®Google Scholar
• Woyach JA, Kloos RT, Ringel MD, et al. Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma. J Clin Endocrinol Metab 2009;94(1):164-70
   PubMed Web of Science ®Google Scholar
• Homsi J, Daud AI. Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors. Cancer Contr 2007;14:285-94
   PubMedGoogle Scholar
• Kebebew E, Peng M, Reiff E, et al. A phase II trial of rosiglitazone in patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer. Surgery 2006;140:960-6
   PubMed Web of Science ®Google Scholar
• Hong DS, Sebti SM, Newman RA, et al. Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies. Clin Cancer Res 2009;15:7061-8
   PubMed Web of Science ®Google Scholar
• Ain KB, Lee C, Williams KD. Phase II trial of thalidomide for therapy of radioiodine-unresponsive and rapidly progressive thyroid carcinomas. Thyroid 2007;17:663-70
   PubMed Web of Science ®Google Scholar
• Mrozek E, Kloos RT, Ringel MD. Phase II study of celecoxib in metastatic differentiated thyroid carcinoma. J Clin Endocrinol Metab 2006;91:2201-4
   PubMed Web of Science ®Google Scholar
• Putzer D, Gabriel M, Kroiss A, et al. First experience with proteasome inhibitor treatment of radioiodine nonavid thyroid cancer using bortezomib. Clin Nucl Med 2012;37:539-44
   PubMed Web of Science ®Google Scholar
• Sherman EJ, Ho AL, Fury MG, et al. A phase II study of temsirolimus/sorafenib in patients with radioactive iodine (RAI)-refractory thyroid carcinoma. 2012 ASCO Annual Meeting. J Clin Oncol 2012;30: abstract 5514
   Google Scholar
• Savvides P, Nagaiah G, Lavertu P, et al. Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid. Thyroid 2013;23:600-4
   PubMed Web of Science ®Google Scholar
• Ha HT, Lee JS, Urba S, et al. A phase II study of imatinib in patients with advanced anaplastic thyroid cancer. Thyroid 2010;20:975-80
   PubMed Web of Science ®Google Scholar
• llouz F, Laboureau-Soares S, Dubois S, et al. Tyrosine kinase inhibitors and modifications of thyroid function tests: a review. Eur J Endocrinol 2009;160:331-6
   PubMed Web of Science ®Google Scholar
• Smallridge RC. Approach to the patient with anaplastic thyroid carcinoma. J Clin Endocrinol Metab 2012;97:2566-72
   PubMed Web of Science ®Google Scholar
• Salaun PY, Campion L, Bournaud C, et al. PhaseII trial of anticarcinoembryonic antigen pretargeted radioimmunotherapy in progressive metastatic medullary thyroid carcinoma: biomarker response and survival improvement. J Nucl Med 2012;53(8):1185-92
   PubMed Web of Science ®Google Scholar